{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:01:47Z","timestamp":1781665307434,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ajo.2023.09.024","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:11:52Z","timestamp":1696259512000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["United States Regulatory Approval of Topical Treatments for Dry Eye"],"prefix":"10.1016","volume":"258","author":[{"given":"David","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2062-3382","authenticated-orcid":false,"given":"Ian J.","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-7966","authenticated-orcid":false,"given":"Gavin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya M.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael X.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7700-207X","authenticated-orcid":false,"given":"Esen K.","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajo.2023.09.024_bib0001","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"12","key":"10.1016\/j.ajo.2023.09.024_bib0002","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/jamaophthalmol.2022.4394","article-title":"Prevalence and incidence of dry eye and meibomian gland dysfunction in the United States: a systematic review and meta-analysis","volume":"140","author":"McCann","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2023.09.024_bib0003","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/eye.2016.186","article-title":"Depression and anxiety in dry eye disease: a systematic review and meta-analysis","volume":"30","author":"Wan","year":"2016","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2023.09.024_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ophtha.2014.07.026","article-title":"Ocular and systemic morbidity in a longitudinal cohort of Sj\u00f6gren's syndrome","volume":"122","author":"Akpek","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2023.09.024_bib0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","article-title":"The economic burden of dry eye disease in the United States: a decision tree analysis","volume":"30","author":"Yu","year":"2011","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajo.2023.09.024_bib0006","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.ajo.2023.09.024_bib0007","doi-asserted-by":"crossref","first-page":"P286","DOI":"10.1016\/j.ophtha.2018.10.023","article-title":"Dry Eye Syndrome Preferred Practice Pattern\u00ae","volume":"126","author":"Akpek","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2023.09.024_bib0008","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","article-title":"Evaluation of topical cyclosporine for the treatment of dry eye disease","volume":"126","author":"Perry","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2023.09.024_bib0009","article-title":"Lifitegrast: a novel drug for patients with dry eye disease","volume":"11","author":"Haber","year":"2019","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.ajo.2023.09.024_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/OPTH.S323301","article-title":"Practical guidance for the use of loteprednol etabonate ophthalmic suspension 0.25% in the management of dry eye disease","volume":"16","author":"Venkateswaran","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2023.09.024_bib0011","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","article-title":"ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease","volume":"41","author":"Wirta","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.ajo.2023.09.024_bib0014","unstructured":"US Food & Drug Administration. Drug approval package: Restasis NDA #021023. Accessed February 27, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-023_Restasis.cfm."},{"key":"10.1016\/j.ajo.2023.09.024_sbref0012","series-title":"Dry eye: developing drugs for treatment guidance for industry\u2013draft. Dry eye","year":"2020"},{"key":"10.1016\/j.ajo.2023.09.024_bib0013","unstructured":"US Food & Drug Administration. Devices@FDA. Accessed December 13, 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/devicesatfda\/index.cfm."},{"issue":"4","key":"10.1016\/j.ajo.2023.09.024_bib0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2023.09.024_bib0018","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2147\/OPTH.S175065","article-title":"A Phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease","volume":"12","author":"Tauber","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2023.09.024_bib43","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye risease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2023.09.024_bib44","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2023.09.024_bib0016","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2023.09.024_bib0020","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2023.09.024_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2023.09.024_bib46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2023.09.024_bib0017","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.ajo.2023.09.024_bib0019","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.ajo.2023.09.024_bib0021","first-page":"221","article-title":"Report of the National Eye Institute\/Industry workshop on Clinical Trials in Dry Eyes","volume":"21","author":"Lemp","year":"1995","journal-title":"CLAO J"},{"issue":"3","key":"10.1016\/j.ajo.2023.09.024_bib0022","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00006324-199303000-00011","article-title":"CCLRU standards for success of daily and extended wear contact lenses","volume":"70","author":"Terry","year":"1993","journal-title":"Optom Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2023.09.024_bib0023","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2023.09.024_bib0024","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul Surf"},{"issue":"12","key":"10.1016\/j.ajo.2023.09.024_bib0025","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2023.09.024_bib0026","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.ajo.2023.09.024_bib0027","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajo.2009.12.003","article-title":"Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension","volume":"149","author":"Katz","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2023.09.024_sbref0028","series-title":"Dry eyes \u2013 regulatory perspectives","author":"Wickstr\u00f6m","year":"2011"},{"key":"10.1016\/j.ajo.2023.09.024_sbref0029","series-title":"Restaysis: Withdrawn application","year":"2018"},{"key":"10.1016\/j.ajo.2023.09.024_sbref0030","series-title":"Xiidra: Withdrawn application","year":"2020"},{"key":"10.1016\/j.ajo.2023.09.024_sbref0031","series-title":"Ikervis","year":"2018"},{"issue":"2","key":"10.1016\/j.ajo.2023.09.024_bib0032","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/09273948.2022.2027461","article-title":"Outcome measures to assess dry eye severity: a review","volume":"30","author":"Hirabayashi","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.ajo.2023.09.024_bib0033","first-page":"240","article-title":"Dry eye: an inflammatory ocular disease","volume":"9","author":"Hessen","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"issue":"10","key":"10.1016\/j.ajo.2023.09.024_bib0034","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ophtha.2018.03.039","article-title":"Effects of prolonged reading on dry eye","volume":"125","author":"Karakus","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2023.09.024_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2023.09.024_bib0036","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S226168","article-title":"Real-world treatment patterns of cyclosporine ophthalmic emulsion and Lifitegrast ophthalmic solution among patients with dry eye","volume":"13","author":"White","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2023.09.024_bib0037","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/jcm8081120","article-title":"Treatment trends in dry eye disease and factors associated with ophthalmic follow-up discontinuation in Japan","volume":"8","author":"Uchino","year":"2019","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.ajo.2023.09.024_bib0038","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0161-6420(97)30125-0","article-title":"Relation between signs and symptoms of dry eye in the elderly. A population-based perspective","volume":"104","author":"Schein","year":"1997","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2023.09.024_bib0039","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jamaophthalmol.2015.0429","article-title":"Variability of tear osmolarity in patients with dry eye","volume":"133","author":"Bunya","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2023.09.024_bib0040","article-title":"Racial and ethnic disparities in dry eye diagnosis and care","author":"Cui","year":"2022","journal-title":"Ophthalmic Epidemiol"},{"issue":"3","key":"10.1016\/j.ajo.2023.09.024_bib0041","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jtos.2019.03.004","article-title":"Natural history of dry eye disease: perspectives from inter-ethnic comparison studies","volume":"17","author":"Wang","year":"2019","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.ajo.2023.09.024_bib0042","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ajo.2015.06.004","article-title":"Ocular complications of primary Sj\u00f6gren syndrome in men","volume":"160","author":"Mathews","year":"2015","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939423004051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939423004051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T08:59:42Z","timestamp":1722157182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939423004051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":46,"alternative-id":["S0002939423004051"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2023.09.024","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"United States Regulatory Approval of Topical Treatments for Dry Eye","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2023.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}